Tessera logo

Tessera Technologies, Inc.


Tessera Stock

Tessera Therapeutics is at the forefront of genetic medicine, pioneering Gene Writing™ technology. This innovative approach aims to treat diseases at their genetic roots by writing therapeutic messages directly into the genome. Tessera's mission is to cure diseases by altering the human genome, providing potentially curative and accessible therapies.

Founded: 2018

Tessera Website

Tessera Company Overview

Tessera Therapeutics is a leader in genetic medicine, advancing the field with its proprietary Gene Writing™ technology. This platform enables precise, permanent modifications to the human genome, offering the potential to treat and cure genetic diseases at their source. By writing therapeutic messages directly into the DNA, Tessera aims to address both small and large genomic alterations, thereby targeting a wide range of genetic disorders with curative potential. Tessera Therapeutics is distinguished by its development of tissue-targeted non-viral delivery systems. These systems ensure that genetic modifications are made accurately within specific tissues, enhancing both the efficacy and safety of the treatments. This approach minimizes off-target effects and maximizes the therapeutic benefits, paving the way for a new era of precision genetic medicine. The company's leadership team is composed of experts in genetic engineering, biotechnology, and pharmaceutical development, all dedicated to pushing the boundaries of what is possible in genetic therapy. Tessera's research and development efforts span various therapeutic areas, focusing on diseases that currently have limited or no treatment options. In addition to its innovative technology, Tessera collaborates with leading academic and industry partners to accelerate the development and commercialization of its therapies. These partnerships are crucial for advancing the clinical applications of Gene Writing™ and bringing new treatments to patients. Tessera Therapeutics' mission is not only to cure genetic diseases but also to make these advanced therapies accessible and affordable. By rewriting the genetic code, Tessera envisions a future where genetic disorders can be corrected at their root cause, providing long-lasting and potentially curative outcomes. Through continuous innovation, rigorous research, and strategic collaborations, Tessera Therapeutics is poised to make significant contributions to the field of genetic medicine, offering new hope and possibilities for patients worldwide.

Management Team

Michael Severino CEO
Howard Liang President and CFO
David Davidson Chief Medical and Development Officer
Jacob Rubens Co-Founder and Chief Innovation Officer
Michael Holmes Chief Scientific Officer
Hari Pujar Chief Operating Officer
Madhusudan Peshwa Chief Technology Officer
Iain McFadyen Chief Data Officer
Becky Lillie Chief Human Resources Officer
Anna-Virginie Eggimann Chief Regulatory Officer

Funding Information